Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Melvin Reichman"'
Autor:
Arturo Bravo-Nuevo, Alice Marcy, Minzhou Huang, Frank Kappler, Jennifer Mulgrew, Lisa Laury-Kleintop, Melvin Reichman, Annette Tobia, George C Prendergast
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e90031 (2014)
Metabolic syndrome, diabetes and diabetes complications pose a growing medical challenge worldwide, accentuating the need of safe and effective strategies for their clinical management. Here we present preclinical evidence that the sorbitol derivativ
Externí odkaz:
https://doaj.org/article/028aec2c386442f4a5d19bc9bf208a09
Autor:
Francesco F. De Pascali, Michael Ippolito, Nathan Hopfinger, Konstantin E. Komolov, Daniela K. Laurinavichyute, Leon A. Sakkal, Ajay P. Nayak, Poli AN. Reddy, Preston S. Donover, Melvin Reichman, Joseph M. Salvino, Raymond B. Penn, Roger S. Armen, Charles P. Scott, Jeffrey L. Benovic
Publikováno v:
ASPET 2023 Annual Meeting Abstract - Cellular and Molecular Pharmacology.
Publikováno v:
ASSAY and Drug Development Technologies. 14:240-251
Glycosyltransferase enzymes play diverse metabolic and regulatory roles by catalyzing the transfer of sugar molecules to protein, lipid, and carbohydrate acceptors, and they are increasingly of interest as therapeutic targets in a number of diseases,
Preclinical study of the long-range safety and anti-inflammatory effects of high-dose oral meglumine
Autor:
George C. Prendergast, Carol M. Artlett, Melvin Reichman, Annette Tobia, Summer Sedano, Arturo Bravo-Nuevo, Allyson R. Minton, Lisa Laury-Kleintop, Alice Marcy, Kaylend Manley, Susan K. Gilmour
Publikováno v:
Journal of cellular biochemistry.
Meglumine is a methylamino derivative of sorbitol that is an approved drug excipient. Recent preclinical studies suggest that administration of high-dose oral meglumine can exert beneficial medicinal effects to treat diabetes, obesity, and fatty live
Autor:
Marlin Yohn, Matthew Sim, Andrew Wright, Amanda R. Schabdach, Preston S. Donover, Melvin Reichman, Chip Allee, Sandesh Gowda
Publikováno v:
Combinatorial Chemistry & High Throughput Screening. 16:180-188
The Lankenau Institute for Medical Research Chemical Genomics Center, Inc. has developed a new (patents issued and pending) Nanotube Automated Repository System (NARS) for dynamic storage of millions of 'single-shot' samples stored in a new monolithi
Autor:
Peter B. Simpson, Melvin Reichman
Publikováno v:
Drug discovery today. 21(5)
Open innovation in pharmaceutical R&D evolved from a triple helix of convergent paradigm shifts in academic, industrial and government research sectors. The birth of the biotechnology sector catalyzed shifts in location dynamics that led to the first
Autor:
Melvin Reichman, Thomas Zielinski, Robert G. Lowery, Amanda R. Schabdach, Lisa Laury-Kleintop, Preston S. Donover, Meera Kumar
Publikováno v:
Journal of biomolecular screening. 20(10)
Ras homologous (Rho) family GTPases act as molecular switches controlling cell growth, movement, and gene expression by cycling between inactive guanosine diphosphate (GDP)- and active guanosine triphosphate (GTP)-bound conformations. Guanine nucleot
Autor:
Lisa Laury-Kleintop, Alice Marcy, Minzhou Huang, Melvin Reichman, George C. Prendergast, Annette Tobia, Arturo Bravo-Nuevo, Frank Kappler, Jennifer Mulgrew
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 2, p e90031 (2014)
PLoS ONE, Vol 9, Iss 2, p e90031 (2014)
Metabolic syndrome, diabetes and diabetes complications pose a growing medical challenge worldwide, accentuating the need of safe and effective strategies for their clinical management. Here we present preclinical evidence that the sorbitol derivativ
Autor:
Melvin Reichman, Peter B. Simpson
Publikováno v:
Nature reviews. Drug discovery. 13(1)
Early-stage drug discovery is rapidly evolving into an endeavour in which scientific research communities in both the public and private sectors are finding new ways to share knowledge, expertise and resources. Here, we discuss some of the challenges
Publikováno v:
Endocrinology. 138:3779-3786
Postmenopausal women receiving hormone replacement therapy have a lower risk of coronary heart disease than women who do not receive hormone treatment. Multiple mechanisms are likely to underlie estrogen’s cardioprotective action, including lowerin